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Abstract 
The Myelodysplastic syndromes are a heterogeneous 
group of hematological malignancies difficult to 
diagnose and classify, for which novel treatments are 
beginning to emerge. Recent advance in diagnosis 
classification, prognosis scoring and genetics 
discovery are presented in this update. 
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Note 
This paper is an update of " Classification of 
myelodysplasic syndromes 1999 " (Flandrin, 2002). 
Clinics and pathology 
Disease 
Myelodysplastic syndromes (MDS) are a 
heterogeneous group of clonal disorders of the 
hematopoietic stem cell (HSC) characterized by 
peripheral cytopenias despite increased 
hematopoïetic precursors, leading to transformation 
into acute myeloid leukemia (AML) in  20-30% of 
cases (Mufti, 2004).  
Clinical manifestations result from cytopenias 
(anemia, infection, and bleeding). Diagnosis is based 
on blood cytopenias and hypercellular bone marrow 
(BM) with dysplasia, with or without excess of 
blasts. 
Phenotype/cell stem origin 
MDS is thought to result from the accumulation of 
genetic or epigenetic (such as promoter 
hypermethylation) lesions, occurring initially in an 
immature progenitor and leading to a proliferative 
advantage of the MDS clone over normal immature 
progenitors. MDS progenitors display abnormal 
terminal differentiation and increased susceptibility 
to apoptosis. These two features explain the clinical 
consequences of blast accumulation and peripheral 
cytopenias (Mufti, 2004). 
Etiology 
Age-induced genetic, epigenetic, and immune-
mediated changes in haemopoietic stem cells (HSC) 
lead to oligoclonal expansion of myelodysplastic 
stem cells, with defective differentiation, 
characterised by increased apoptosis of erythroid and 
myeloid progenitors (Corey et al., 2007). 
Microenvironmental changes and immune 
deregulation contribute to this differentiation defect. 
Congenital bone marrow failure syndromes as 
Fanconi's anemia (FA), neurofibromatosis, 
dyskeratosis, Down syndrome  and familial platelet 
disorder  (associated with germ line mutations of 
RUNX1 or CEBPa) predispose to MDS/ AML. 
Epidemiology 
The median age at diagnosis is approximately 70 
years.  
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Table 1: WHO classification for MDS (Vardiman et al. 2009) 
 
The incidence is 4 to 5 per 100,000 persons per year. 
The etiology is generally unknown, the role of 
exposure to environmental chemical and physical 
mutagens is sometimes suspected. In 15 to 20% of 
cases, however, MDS are secondary (sMDS) to 
chemotherapy and/or radiotherapy for a prior illness, 
usually cancer. More rarely, they are secondary to 
exposure to benzene or other aromatic hydrocarbons, 
or products used in agriculture. 
Cytology 
MDS have received a variety of nomenclatures, until 
the first international classification by the French 
American British (FAB) group in 1982 (Bennett et 
al., 1982). This classification has been refined in 
2001 then in 2008 by a WHO expert committee 
(Vardiman et al, 2002; and 2009), integrating novel 
prognostic factors in MDS, such as multilineage 
dysplasia. The marrow blast threshold of AML was 
lowered from 30% to 20%. This classification also 
designed the term MDS/MPN (Myeloproliferative 
Neoplasm) to regroup a heterogeneous set of rare 
entities including chronic myelomonocytic leukemia 
(CMML), previously considered as a MDS.  
Three minimal criteria must be met for the diagnosis 
of MDS: 1) persistent (> 6 months) and significant 
cytopenia(s) (Hb < 10 g/dL, absolute neutrophil 
count < 1.8 G/L, platelets < 100 G/L), 2) significant 
bone marrow dysplasia, or blast excess or typical 
cytogenetic abnormality, and 3) exclusion of 
differential diagnoses (Kaloutsi V et al., 
1994;Bennett et al., 2009).  
Presence of dysplasia is the first key criterion for 
diagnosis and prognosis of MDS.  
A given lineage is considered dysplastic if two or 
more dysplastic features are found on > 10% cells. 
Multilineage dysplasia (MD) is defined as the 
coexistence of dysplasias in two or more lineages. 
Blast excess is frequent in MD but 40-60% of cases 
occur without blast excess.  
The term idiopathic cytopenias of undetermined 
signification (ICUS) has been coined to account for 
cases when differential diagnoses have been 
excluded, but cytopenias or dysplasias do not reach 
significant MDS diagnostic thresholds. The outcome 
of ICUS still remains undetermined, but probably 
evolves sometimes into MDS, and thus requires 
blood and BM monitoring (Wimazal et al., 2007).  
Ringed sideroblasts (RS), ie. sideroblasts with ? 5 
siderophilic granules contouring at least a third of the 
nucleus circumference, are not specific of MDS as 
they can be encountered in a variety of conditions 
such as alcohol consumption, copper deficiency or 
zinc excess, as well as a rare congenital condition 
called X recessive sideroblastic anemia. RS are 
considered significant when they represent > 15% of 
erythroid cells. However, in the absence of blast 
excess, RS define an entity with favourable 
prognosis, termed refractory anemia with ringed 
sideroblasts (RARS).  
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Table 2a: Karyotype (IPSS-R) - AML =acute myeloid leukaemia. NR = not reached. 
 
Auer rods have historically been recognized as a 
poor prognostic marker and remain considered in the 
WHO classification.  
Some morphologies can be strongly evocative of a 
precise underlying cytogenetic or genetic aberration. 
For instance, a characteristic dysgranulopoiesis 
combining pseudo-Pelger-Huüt anomaly and small 
vacuolated neutrophils has been associated with 17p 
deletions and TP53 tumour suppressor gene 
mutations (Lai et al., 1995). The "5q- syndrome" 
which was recognized in 2001 by the WHO 
classifications also has a distinct morphology.  
Precise count of BM blasts is the second central 
criterion for diagnostic and prognostic classification 
of MDS. Myeloblasts are consensually defined by a 
high nuclear/cytoplasmic ratio and diffuse chromatin 
pattern, can be "agranular" or "granular". A third 
class of blasts defined by the presence of numerous 
(>20) azurophilic granules is included in the blast 
percentage, and can be distinguished from 
promyelocytes by the lack of Golgi structure (Mufti 
et al., 2008)  
Pathology 
BM biopsy first allows objective evaluation of BM 
cellularity, which physiologically declines with age. 
Application of a standardized age correction to 
cellularity brings the incidence of "hypoplastic" 
MDS from 29% to 7% (Thiele et al., 2005). 
Hypoplastic MDS raises the question of the 
differential diagnosis with aplastic anemia (AA). 
Features of MDS are the presence of circulating 
myeloblasts, megakaryocytic or granulocytic 
dysplasia. Mild erythroid dysplasia can be seen in 
AA. Other MDS criteria include abnormal 
sideroblasts, presence of two or more blast cell 
clusters. Clusters (3-5 cells) or aggregates (> 5 cells) 
of blasts cells away from endosteal or vascular 
niches, in the central portion of the BM, have been 
dubbed "abnormally localized immature myeloid 
progenitors" (ALIP). ALIP have been proposed as 
diagnostic and prognostic markers.  
Immunohistochemistry with a CD34 antibody marks 
immature hematopoietic progenitors and 
megakaryocytes, and can be used to asses the blast 
percentage.  
However, some MDS have CD34- blasts in MDS: in 
those cases, CD117 has been proposed as a surrogate 
marker.  
Some authors have proposed that the presence of 
CD34+ cell clusters may better reflect prognosis 
than CD34+ cell percentage. 
Treatment 
Treatment varies from symptomatic treatment of 
cytopenias, especially by transfusions for anemia, to 
allogeneic stem-cell transplantation. Treatment of 
patients with lower-risk myelodysplastic syndromes 
includes growth factors and lenalidomide. Higher-
risk patients are treated with hypomethylating agents 
and, allogeneic stem-cell transplantation whenever 
possible (Fenaux et al. 2009). 
Evolution 
Progression to acute myeloid leukaemia depends on 
prognosis factors. Rare cases progress to aplastic 
anemia. 
Prognosis 
Prognostic evaluation in MDS still largely relies on 
an International Prognostic Scoring System (IPSS) 
established on the basis of an international cohort of 
patients (IMRAW cohort) treated symptomatically 
and recently revised (IPSS-R) (Greenberg et al, 
1997; and 2012). IPSS relies on number of 
cytopenias, marrow blast percentage and 
cytogenetic. Patients are regrouped into four risk 
categories (low, intermediate 1 and 2, and high).  
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Table 2b: IPSS-R Prognostic Score Values - ANC: Absolute neutrophil count, BM: bone marrow 
 
 
Table 2 c: IPSS-R Prognostic risk Categories/Scores 
 
The IPSS has since been validated in many 
therapeutic contexts including intensive 
chemotherapy and allogeneic stem cell 
transplantation (ASCT). IPSS categories are often 
regrouped into lower-risk MDS (IPSS low and 
intermediate-1), and higher-risk MDS (IPSS 
intermediate-2 and high). Lower-risk MDS are 
patients with prolonged survival where the main 
objectives are to cope with chronic cytopenias 
notably anaemia, and to defer ASCT. On the other 
hand the treatment in higher-risk MDS should alter 
disease history and prolong survival. The approval 
of azacytidine in higher-risk underscores the 
importance of IPSS evaluation in all patients at 
diagnosis.  
According to the IPSS-R, 27% of the lower-risk 
MDS patients of the original IPSS are reclassified as 
having a higher risk and they potentially need a more 
intensive treatment. Conversely18% of high-risk 
MDS patients, as defined by the original IPSS, are 
reclassified as low risk by the IPSS-R.  
Genetics 
Clonality assays based on gene imprinting 
(HUMARA assays) have historically been the first 
molecular tools to confirm the clonal nature of 
normal karyotype MDS. They still can serve as 
diagnostic co-criterion, but novel genomic tools are 
now available that can both confirm clonality and 
provide valuable prognostic information. (Bejar R et 
al 2011) 
Cytogenetics 
Cytogenetics morphological 
Conventional cytogenetic in de novo MDS is  
abnormal in 35-40% of patients by conventional 
banding karyotyping, and cytogenetic aberrations 
are highly heterogeneous.  
Abnormal karyotype, especially those of 
unfavourable prognosis, are more frequent in cases 
with blast excess, with 75% RA presenting with 
Normal karyotype (NK), compared to 25-50% 
abnormal karyotype in RAEB1-2, or secondary 
MDS (80% versus 40% in de novo MDS).  
The most frequent types of abnormalities by 
frequency order are total or partial chromosome 
losses, total or partial chromosome gains, and 
unbalanced translocations. Balanced translocations 
are rare.  
Frequent alterations represent 40% of all abnormal 
karyotypes, including partial or total deletion of 
chromosome 5 (?5/5q?), partial or total deletion of 
chromosome 7 ( -7/del(7q)), trisomy 8 (+8), partial 
deletion of chromosome 20 (del(20q)), and Y 
chromosome loss (?Y). These last alterations are not 
specific of MDS and can be encountered in AML or 
in myeloproliferative neoplasm. Loss of 
chromosome Y can be found in elderly healthy 
subjects (Wiktor et al, 2000). Trisomy 8 and loss of 
Y may be present in a constitutional mosaicism. 
Thus a constitutional karyotype on blood sample 
cultivated with phytohemaglutin as mitogen can be 
performed in those two cases for correct 
interpretation of cytogenetic response after intensive 
therapy or transplantation.  
Chromosome 5 and 7 alterations and other 
infrequent alterations in AML are considered as 
"myelodysplasia related changes" in the current 
WHO classification, as they may reflect an 
underlying undiagnosed myelodysplasia. The 
remaining 60% of abnormal karyotype display rare 
alterations  
Classification of myelodysplastic syndromes 2015 Eclache V 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2016; 20(3) 159 
 
Del5q and the "5q- syndrome"   
Interstitial deletion of the long arm of chromosome 
5 (del(5q)), is the most frequent cytogenetic 
aberration in MDS, occurring in 15% of patients. 
The "5q- syndrome" first described by Van den 
Berghe in 1974, is characterized by an isolated 
del(5q) and absence of PB or BM blast excess, and 
is now part of WHO classifications (Vardiman et al, 
2008). Isolated del(5q) is favourable in the IPSS. The 
distinct morphologic features of 5q- syndrome 
include thrombocytosis in a third of patients, 
macrocytic anemia, and hypolobulated 
megakaryocytes, contrasting with little dysplasia 
along the granulomonocytic and erythroid lineages. 
The erythroid lineage may often be hypoplastic. 
Prognosis is favourable, with a prolonged overall 
survival and a low risk of progression to AML. 
Clonal evolution is also rare without treatment. The 
prognosis is in fact dominated by the consequences 
of chronic transfusions, but these patients 
dramatically respond to the immunomodulatory 
agent lenalidomide, with two thirds reaching long-
term transfusion independency (Raza et al, 2008).  
The 5q deletion is variable in size, but invariably 
affects the q31 to q33 bands. A common 5q33 
deletion spanning over 1.5 Mb and encompassing 42 
genes has been delineated. The lack of recurrent 
point mutation or of cryptic deletion on the normal 
5q allele supports an haploinsufficiency model 
whereby loss of a single copy of one or more 
probably several genes cause 5q syndrome. Several 
candidate genes have been implicated including 
SPARC, CTNNA1, EGR1, and RPS14. 
Haploinsufficiency for the ribosomal subunit RPS14 
induces a P53-dependent block in erythroid 
proliferation and differentiation, whereas 
haploinsufficiency of two micro-RNAs, MIR145 
and MIR146a, leads to dysmegakaryopoiesis and 
thrombocytosis (Ebert et al, 2008).  
Patients with blast excess or additional cytogenetic 
aberrations can also harbour del(5q) but the 
prognosis is much more unfavourable than 5q- 
syndromes.  
Trisomy 8   
Trisomy 8 +8, (10-15%) that sometimes results from 
germinal mosaicism, is often subclonal, fluctuating 
independently of blast counts. This suggests it is a 
secondary lesion in MDS.  
 Monosomy 7 / deletion 7q   
Chromosome 7 anomalies including del(7q), 
monsomy 7 (-7/del(7q)), or more rarely t(1;7), are 
second in frequencies after del(5q) (10%) and have 
almost invariably been assigned a poor prognostic 
value in terms of both survival and transformation 
risk. Different minimal regions of deletion have been 
described in 7q35-36, possibly with distinct 
prognostic values. Monosomy 7 can transform 
constitutional bone marrow failures syndromes (FA, 
Down syndrome) or AA, or arise after radiation or 
toxic exposure. It is the most frequent alteration in 
childhood MDS where it is often accompanied by a 
degree of myeloproliferation. There also is in vitro 
evidence that G-CSF treatment may select a -7 clone, 
and that 7q is a genetically instable region. Patients 
with -7/del(7q) have neutrophil functional 
impairment, and thus may present severe infections 
despite moderate neutropenia.  
Those patients poorly respond to intensive 
chemotherapy but interesting results have been 
described with ypomethylating agents (Fenaux et al., 
2009).  
 3q26 abnormalities   
Other reputed pejorative abnormalities considered in 
the IPSS-R include the 3q26 alterations 
inv(3)(q21q26), and t(3;3)(q21;q26) that rearrange 
the MECOM (MDS1/EVI1) locus with complex 
oncogenic roles and may be associated with 
thrombocytosis. Numerous other partners of EVI1 
are known as  PRDM16  in t(1;3)(p36;q21) and 
RUNX1  in t(3;21)(q26;q22). 
 17p- / -17 and TP53 mutations   
17p deletion, monosomy 17, unbalanced 
translocation or isochromosome 17 which involve 
the loss of one TP53 locus are found mainly in 
sMDS/AML after chemotherapy and/or 
radiotherapy, usually in association with other 
complex chromosomal anomalies. There is an 
association between vacuolated pseudo-Pelger-Huet 
granulocytes and chromosome 17p deletion with 
consistent involvement of TP53 gene located at 
17p13. It occurs in MDS and AML with poor 
prognosis.  Some reports pinpoint the strong 
association of TP53 mutations and 5q deletion in 
MDS (Jädersten et al, 2011). 
 Others abnormalities  
Other favourable aberrations in the IPSS include 
del(20q) which is not specific of MDS, and has been 
associated with a specific presentation  involving 
frequent thrombocytopenia.  
Recurrent unbalanced translocations involving 1q 
have been found in primary MDS with a partial 
trisomy for the long arm of chromosome 1. Such 
rearrangements are described as t(1;15)(q11;p11); 
t(Y;1)(q12;q12), der(16) t(1;16)(q11;q11). In 
secondary MDS translocation with the long arm of 
chromosome 7 is not rare.  
Deletion 9q, del(11q), del(12p)  and del(13q)  are 
recurrent in MDS. MDS presenting with deletion of 
the short arm of chromosome 12, del(12p) are 
heterogeneous. Association with multiple karyotypic 
changes in sMDS is more common than de novo 
disorders with a 12p- chromosome as a sole 
aberration. Deletions are usually interstitial, with 
loss of material between band p11 and p13. FISH 
method has been used to show that both ETV6 and 
the gene for an inhibitor of a G1 cyclin-dependant 
protein kinase (CDKN1B) are deleted in all myeloid 
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malignancies with a del(12p) including MDS 
(Haferlach et al, 2011).  
Acquired monosomy X has been sporadically found 
in female MDS patients. Xq13 may also be involved 
in translocations in MDS, as well as in 
rearrangements such as an isodicentric chromosome 
X with breakpoint at q13 (idic(X)(q13)).  
 Complex karyotypes  
Complex karyotypes (15%) are conventionally 
defined as the coexistence of at least 3 anomalies that 
are thought to result from alterations in DNA repair 
or checkpoint signalling. Complex karyotypes are by 
essence heterogeneous, with a prognosis worsening 
with each additional aberration, rather than by the 
chromosomes involved (most frequently, 5, 7 and 
17). Complex karyotypes are highly chemoresistant, 
but interesting results with the hypomethylating 
agent decitabine have been observed, that need to be 
confirmed on larger cohorts.  
 Rare translocations 
t(2;11)(p21;q23) implicate miR-
125b1;t(6;9)(p22;q34)  leads to DEK/NUP214 
fusion. 
 Clonal evolution  
New rearrangements frequently occur, with disease 
progression. Limited data is available on the 
prognostic value of clonal evolution, but it is 
generally considered pejorative, as higher-risk 
aberrations appear. 
Genes involved and 
proteins 
Note 
Somatic mutations are observed in approximately 
80% of the MDS (Bejar et al, 2011). The most 
common genes are those involved in epigenetic 
regulation (TET2 , ASXL1, EZH2, DNMT3A, 
IDH1, IDH2  (Kosmider et al, 2009), splicing 
(SF3B1, correlated to RARS, SRSF2, U2AF35, 
ZRSR2)( Damm et al, 2012), transcription (RUNX1 
, ETV6, CBL, NRAS  , KRAS, NF1, PTPN1, TP53) 
and less often cohesin genes. TP53 mutated 
subclones may occur at early disease stage in MDS 
with del(5q) where they are associated with a lower 
response to lenalidomid and an increases risk of 
progression. (Jädersten et al, 2011).  
It has recently been described that approximately 
half of RARS with thrombocytosis (RARS-T) 
patients, along with a small subset of other MDS and 
mixed myelodysplastic/ myeloproliferative 
disorders, carry the JAK2 V617F mutation, and 
scarcely MPL mutations. RARS-T patients show 
clinical features of both RARS, essential 
thrombocytemia and to some extent myelofibrosis. 
However, the degree of anaemia and overall survival 
is more similar to RARS than to myeloproliferative 
disorders (Hellström-Lindberg et al., 2008)  
Over expression of the EVI1 gene is found in one 
third of MDS patients, particularly those with blast 
excess, even  without 3q26 rearrangement in 
conventional cytogenetic.  
As in AML, the WT1 transcription factor is also over 
expressed in virtually all cases of MDS with blast 
excess, but also in a third of lower-risk MDS. The 
leukemogenic potential of this lesion is still unclear, 
but its over expression can provide a tool for minimal 
residual disease (MRD) monitoring in the context of 
intensive therapy, like in AML. 
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